Treatment of deep vein thrombosis (DVT) has changed and evolved with discovery of new drugs and modern invasive methods of diagnosis and treatment. To date, anticoagulation is the generally accepted approach for DVT of the lower extremities. At the same time, endovascular treatment of these patients is interesting. These methods include catheter thrombolysis, endovascular mechanical thromboextraction and their combination. Large-scale randomized clinical trials have shown that such interventions are not advisable in all patients with DVT. Effectiveness and feasibility of these interventions are determined by such criteria as age, DVT extent, severity of symptoms and duration of disease. The most perspective group for endovascular treatment of DVT are patients with iliofemoral thrombosis, as well as patients younger than 65 years and those with severe symptoms (Villalta score > 15). Optimal timing for such interventions is unclear. Early interventions may be more effective considering pathophysiological changes in the thrombus over time. When planning catheter thrombolysis, we should analyze risk-to-benefit ratio, absolute and relative contraindications. Currently, there are devices for endovascular thromboextraction from various veins. Each tool has different properties depending on clinical objective.
Background: Pulmonary embolism (PE) patients are generally admitted to the hospital, which leads to significant burden on healthcare systems. Many PE patients are hemodynamically stable and can be ambulated safely. Direct oral anticoagulants (DOACs) do not need routine laboratory monitoring, which makes them a convenient option for outpatient care. Data on the outpatient management of PE patients using DOACs are scarce. Methods: We conducted a systematic search of MECENTRAL databases to identify randomized controlled trials (RCTs), non-randomized studies (non-RCTs), retrospective studies, reviews, systematic reviews, meta-analyses, and clinical guidelines evaluating the use of DOACs for outpatient treatment of PE patients. Results: A total of 833 publications were identified, and eight studies—two RCTs and six non-RCTs (two retrospective and four prospective)—were finally included. These studies reported rates of bleeding events, recurrent venous thromboembolism (VTE), PE-related mortality, and all-cause mortality among outpatients who received DOACs. No PE-related deaths were reported in any of the included studies. Bleeding events were reported in five studies, and recurrent VTE rates were reported in two studies. Study findings showed that the sPESI score has some disadvantages in selecting patients for home treatment. The quality of the studies varied considerably. A meta-analysis could not be performed due to heterogeneity in the study designs, patient populations, and outcome reporting. While the treatment results favored outpatient management of selected PE patients, no robust conclusions could be drawn from the published data. Conclusions: Outpatient treatment of PE with DOACs has some potential as an approach for managing selected patients. Hestia, POMPE-C and RESI scores are preferable for selecting PE patients for home treatment, but utilizing sPESI as the only tool has to be avoided. Apixaban and rivaroxaban are both safe, with a low bleeding risk. Large-scale prospective studies are required to establish the efficacy and safety of outpatient PE management using DOACs.
Venous thromboembolism (VTE) is still a major challenge in clinical medicine involving specialists in all professional spheres. In-hospital treatment of VTE is a traditional option. However, the feasibility of outpatient treatment of VTE has been investigated since the 1990s. The modern European clinical guidelines advocate for outpatient care in patients meeting specific criteria. Approximately 30—55% of VTE patients, including those with low-risk pulmonary embolism, may be discharged after a brief hospitalization (<24 hours) or managed outside of the hospital. Outpatient VTE management offers several benefits, such as lower risk of complications associated with hospital-stay, potential cost savings for healthcare system and higher quality of life with earlier return to physical and professional activities. Despite these advantages, the majority of patients diagnosed with VTE admit to the hospitals. We reviewed modern approaches to VTE treatment, in particular deep vein thrombosis and pulmonary embolism, and explores indications for outpatient management of patients with these diseases. We provide an overview of relevant literature, researches and international guidelines.
Objective. To evaluate the efficacy and safety of outpatient treatment of pulmonary embolism (PE) using standard anticoagulant therapy (ACT) with direct oral anticoagulants. Material and methods. A prospective, observational study was conducted in patients with PE. The analysis included fifty patients with a first-time diagnosis of PE who received outpatient treatment. Outpatient management was defined as discharge from the emergency (diagnostic) department after completion of additional evaluation and confirmation of PE. The primary outcomes were the incidence of symptomatic recurrent venous thromboembolism (VTE) and bleeding events following initiation of ACT. Secondary outcomes included VTE-related mortality and all-cause mortality, readmission to emergency departments, and non-adherence to ACT. Results. The mean age of patients was 65±10 years, with a predominance of women (n=29; 58%). The most common presenting symptoms were lower extremity edema (24%) and dyspnea (16%). PE involved the segmental and subsegmental pulmonary arteries in 84% of patients, submassive PE was diagnosed in 10% of subjects, and massive PE — in 4%. Furthermore, 44 (88%) of patients developed PE in addition to oncological disease. Recurrent VTE within 3 months was observed in 1 (2%) patient. No major or clinically relevant bleeding events occurred, and minor bleeding was reported in 1 (2%) patient. Non-adherence to ACT was noted in 2 (4%) patients. During the study, five deaths (10%) occurred, none of which were VTE-related. Conclusion. Outpatient management of hemodynamically stable patients with pulmonary embolism is effective and safe when proper risk stratification and careful evaluation of individual complication risks are ensured.
Venoactive Drugs (VADs) are an integral part of the conservative management of chronic venous diseases (CVD). The mechanism of action of these drugs is well-described. It targets key ways of pathogenesis of CVD, such as loss of venous tone, chronic inflammation in the venous wall and its subsequent remodeling, increased capillary permeability, and insufficient compensatory function of the lymphatic system. The clinical efficacy of VADs concerning quality of life, CVD signs and symptoms, has been demonstrated in numerous randomized controlled trials (RCTs), meta-analyses, and systematic reviews. The incidence of adverse events appears to be low, and the use of VADs is considered a safe method of treatment for CVD symptoms. The most extensively studied group of VADs are flavonoids, which include drugs based on diosmin and rutosides. Diosmin, a principal flavonoid used in drugs, exhibits pleiotropic effects. It slows the degradation of norepinephrine in the venous wall, potentiating its effect and enhancing venous tone. Diosmin possesses anti-inflammatory activity by inhibiting leukocyte adhesion and the synthesis of pro-inflammatory mediators. It decreases capillary and venule permeability, which is directly associated with reduced fluid movement into the tissues. RCTs show that diosmin is effective in managing diseases of other organs and systems which also present with edema.
Outpatient management and early discharge for patients with pulmonary embolism (PE) who are at low and intermediate-low risk for early mortality are emerging approaches that are gaining increased attention. Objective. This study aims to evaluate the efficacy and safety of different management strategies for patients with PE: early hospital discharge, outpatient care, and standard inpatient treatment. Material and methods. The study cohort comprised 127 patients recently diagnosed with PE, categorized into those with hospital stays of 3–4 days (early discharge) or 5 days or more (standard inpatient treatment), as well as patients receiving outpatient care. The primary efficacy outcome measured was the incidence of symptomatic recurrent venous thromboembolism (VTE) and/or VTE-related death following the initiation of anticoagulant therapy. The primary safety outcome assessed was the bleeding rate, along with evaluations of VTE-related and all-cause mortality rates. Results. The outpatient group included 50 patients, the early discharge group 37, and the standard inpatient group 40. The mean ages were 65±10, 63.6±12.1, and 61.5±12.4 years, respectively. No fatal VTE recurrences were reported in any group. Bleeding rates were 2% (1 patient) in the outpatient group, 5.4% (2 patients) in the early discharge group, and 0% in the standard inpatient group (p=1). Re-admission rates were similar across the groups: 2 patients (4%) in the outpatient group, 1 patient (2.7%) in the early discharge group, and 1 patient (2.5%) in the standard inpatient group (p=1). The rates of VTE recurrence were comparable among the groups. Chronic heart failure emerged as the only potential predictor for VTE recurrence (odds ratio [OR] 5.02; 95% confidence interval [CI] 1.03–24.51). Outpatient management did not lead to an increased rate of VTE recurrence (OR 0.63; 95% CI 0.12–3.35). Conclusion. Both outpatient management and early discharge for hemodynamically stable patients with PE at low and intermediate-low risk of 30-day mortality are safe and effective alternatives to standard inpatient treatment.